Nottingham Advisors, Inc. Revance Therapeutics, Inc. Transaction History

Nottingham Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$24.7 - $37.61 $4,940 - $7,522	-200 Reduced 1.64%	11,979 $303,000
Q1 2023 May 12, 2023	SELL	$18.36 - $35.27 $20,801 - $39,960	-1,133 Reduced 8.51%	12,179 $392,000
Q2 2020 Aug 10, 2020	BUY	$12.6 - $26.55 $25,200 - $53,100	2,000 Added 17.68%	13,312 $349,000
Q1 2020 Apr 20, 2020	BUY	$12.46 - $27.81 $16,297 - $36,375	1,308 Added 13.07%	11,312 $167,000
Q4 2019 Jan 31, 2020	SELL	$11.66 - $20.15 $23,320 - $40,300	-2,000 Reduced 16.66%	10,004 $162,000
Q3 2019 Oct 30, 2019	BUY	$10.22 - $14.5 $20,440 - $29,000	2,000 Added 19.99%	12,004 $156,000
Q1 2019 Apr 11, 2019	SELL	$15.4 - $20.39 $20,143 - $26,670	-1,308 Reduced 11.56%	10,004 $158,000
Q2 2018 Feb 13, 2020	SELL	$27.45 - $33.35 $54,900 - $66,700	-2,000 Reduced 15.02%	11,312 $348,000
Q2 2018 Aug 07, 2018	BUY	$27.45 - $33.35 $54,900 - $66,700	2,000 Added 17.68%	13,312 $365,000
Q3 2017 Oct 23, 2017	BUY	$22.55 - $28.1 $255,085 - $317,867	11,312	11,312 $312,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Nottingham Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Nottingham Advisors, Inc. with notifications on news.